Next Article in Journal
Effects of Physical Exercise Program in Adults with Intellectual and Developmental Disabilities—A Study Protocol
Previous Article in Journal
Understanding the Effect of Multiple Sclerosis on General and Dimensions of Mental Health
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 11
Issue 24
10.3390/jcm11247484
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Immune-Mediated Diseases Following COVID-19 Vaccination: Report of a Teaching Hospital-Based Case-Series

by
Eric Liozon
1,*,
Matthieu Filloux
2,
Simon Parreau
1,
Guillaume Gondran
1,
Holy Bezanahary
1,
Kim-Heang Ly
1 and
Anne-Laure Fauchais
1
1
Departments of Internal Medicine, Dupuytren University Hospital, 87042 Limoges, France
2
Department of Immunology and Immunogenetics, University Hospital of Limoges, 87042 Limoges, France
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2022, 11(24), 7484; https://doi.org/10.3390/jcm11247484
Submission received: 24 November 2022 / Revised: 11 December 2022 / Accepted: 14 December 2022 / Published: 16 December 2022
(This article belongs to the Section Epidemiology & Public Health)
Browse Figure
Versions Notes

Abstract

:
The occurrence and course of immune-mediated diseases (IMDs) following COVID-19 vaccination has been little explored so far. We retrieved, among adult patients hospitalized at the Internal Department of a French university hospital up to May 2022, all those who had developed, or relapsed to, an IMD less than 3 weeks following COVID-19 vaccination, without other triggers. Twenty-seven (24 new-onset) post-COVID-19 vaccine IMDs were recorded. They comprised giant cell arteritis or polymyalgia rheumatica (n = 16, HLA-DRB1*04 in 58% of 12 assessed GCA cases), immune-mediated necrotizing myositis or acute rhabdomyolysis, systemic vasculitis, immune thrombocytopenic purpura, rheumatoid arthritis, anti-synthetase syndrome, and adult-onset Still’s disease. The causative vaccines were mRNA-based (20 cases) or viral vector-based (7 cases). The IMD typically occurred after the first vaccine dose, with an average delay of 8 (5 SD) days. The patients’ mean age was 67 years, and 58% were women. The IMDs had protracted courses in all but three of the patients and typically required high-dose glucocorticoids, in combination with immunomodulators in 13 patients. One patient died of intractable rhabdomyolysis, whereas five suffered permanent damage from IMDs. Eleven patients with well-controlled IMDs completed their COVID-19 vaccination schedule, and two suffered mild IMD relapses. There is a risk of IMDs, notably GCA/PMR, and muscle disorders, following COVID-19 vaccination. Such adverse reactions typically occurred after the first dose, raising concern about subsequent COVID-19 vaccinations. However, early re-challenge in well-controlled IMDs appeared safe.

1. Introduction

The speed and severe impact of the coronavirus disease 2019 (COVID-19) pandemic led to rapid development of vaccines. Phase-II trials have shown reassuring safety profiles in mRNA-based vaccines and viral vector-based vaccines [1,2,3]. Likewise, cross-sectional or longitudinal studies on the safety of several COVID-19 vaccines in autoimmune inflammatory rheumatic diseases did not detect a risk signal [4,5]. Nevertheless, recent safety data from population-wide surveys have suggested significant side effects, notably severe thrombotic events via vaccine-induced immune thrombotic thrombocytopenia [6]. Although vaccines are linked to several immune-mediated diseases (IMDs) [7,8,9,10,11,12,13], such reports on COVID-19 vaccines are limited, beside single case reports, to a few case-series [14,15,16,17]. Therefore, we evaluated the occurrence, or flare-up, of IMDs reported in the Internal Medicine Department of a University Hospital during the period of mass vaccination against COVID-19.

2. Methods

2.1. Study Design

Starting in January 2021, when COVID-19 vaccination became progressively available, we retrieved all reports of IMDs occurring after vaccination among consecutively hospitalized patients hospitalized in the Internal Medicine Department of a University Hospital. The catchment area of the hospital roughly corresponds to the population of the Limousin region, e.g., 723,784 people, 436,360 being over 40 years of age. As of 31 May 2022, at study termination, 82% of the regional population were vaccinated at least once against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). However, precise calculation of the regional incidence of post-COVID-19 vaccine IMDs cannot be obtained, since it is expected that not all patients with an IMD will be referred, or reported, to the regional hospital. Details regarding the demographic information, significant comorbid conditions, date of diagnosis, clinical features, biological abnormalities at disease onset, use of glucocorticoid treatments including pulse methylprednisolone and/or prednisone, use and type of steroid-sparing agents, relapses during prednisone tapering, survival, recovery from IMD, and total duration of treatment were retrieved for each patient. We also aim to assess the influence of HLA-DRB1/DQB1 polymorphism on COVID-19 vaccine-induced IMDs, in particular the frequency of HLA-DRB1*01 and DRB1*04 alleles. Both alleles are risk factors for autoimmune/auto-inflammatory syndrome induced by adjuvants (ASIA) [8].

2.2. Case Series

Inclusion criteria: The case series comprised cases of giant cell arteritis (GCA), polymyalgia rheumatica (PMR), immune-mediated necrotizing myositis (IMNM) or acute rhabdomyolysis, ANCA-associated vasculitis (AAV), Henoch-Shönlein purpura (HSP), adult-onset Still’s disease (AOSD), rheumatoid arthritis (RA), and idiopathic thrombocytopenic purpura (ITP) following COVID-19 vaccination. The inclusion criteria were (a) IMD diagnosed using currently accepted criteria. GCA was diagnosed based on the criteria of the American College of Rheumatology [18]; negative biopsy cases were regarded as true GCA cases provided there was a dramatic and sustained response to corticosteroid treatment. PMR was diagnosed using the 2012 EULAR/ACR criteria [19]. Rheumatoid arthritis was diagnosed using the 2010 EULAR/ACR classification criteria [20]. IMNM was characterized by proximal muscle weakness, a high serum creatine kinase level, widespread inflammatory muscle involvement on magnetic resonance imaging, myofiber necrosis with minimal inflammatory cell infiltrate on muscle biopsy, and no or little extra-muscular involvement, with or without specific autoantibodies in serum [21]. Diagnosis of the one case of eosinophilic granulomatosis with polyangiitis (EGPA) was based on the patient’s history of allergic asthma, blood eosinophilia 3.6 × 109/L, multiple mononeuropathy, and ANCA positivity (anti-myeloperoxydase 49 UI/L). In this patient, peripheral nerve biopsy was considered unnecessary. In a patient with a prior diagnosis of AOSD that met most of Yamaguchi’s criteria [22], a late relapse following vaccination was ascertained by a flare-up of arthritis in both wrists and knees together with increased CRP and ferritin levels. ITP was defined as a platelet count persistently <100 G/L with exclusion of other causes of thrombocytopenia. Diagnosis of Henoch-Shönlein purpura (HSP) was based on the presence of at least three of the criteria of the American College of Rheumatology [23]. (b) No symptom or sign suggesting an IMD before vaccination. (c) The interval between vaccination and IMD onset did not exceed 3 weeks (in order to minimize the play of chance). (d) No other trigger (viral including current or recent SARS-CoV-2 or bacterial infection, or inciting drug) was evident. If a patient had been vaccinated at least twice (i.e., COVID-19 and influenza vaccination) within 3 weeks of IMD onset, responsibility was arbitrarily assigned to the vaccine received closest to IMD onset. (e) No spontaneous improvement of IMD; immunosuppressive/immunomodulatory treatment was required. Written informed consent was obtained from each patient.
HLA-DRB1/DQB1 genotyping: HLA-DRB1/DQB1 genotyping was conducted using peripheral blood samples in 20 patients. To assess the presence of COVID-19 vaccine-associated HLA specificities in the subset of GCA/PMR, we compared the results of HLA-DR typing of 58 patients, comprising 14 patients with COVID-19 vaccine-induced GCA or PMR, 11 with other vaccine-induced (influenza vaccine, or pneumococcal vaccine) GCA, 17 with familial aggregation of GCA or PMR and, a random sample of 16 patients with GCA (e.g., without a vaccine trigger or familial aggregation). Familial cases occurring after a vaccination were arbitrarily included in the corresponding post-vaccination group.

3. Results

Characteristics of the cohort: Thirty-seven reports were scrutinized for a possible relationship between IMD onset and vaccination. Three reports were excluded due to inconsistent temporal relationships. Four patients (Sjögren’s syndrome, systemic lupus, sarcoidosis, PMR), who reported self-limited inflammatory musculoskeletal or dermatological (sarcoidosis) manifestations soon after vaccination, were also excluded. Thirty post-vaccine disorders qualifying as IMDs were recorded within the study timeframe, 27 of which (90%; 22 new onset, 4 relapses) occurred after COVID-19 vaccination. These comprised 12 cases of GCA, four of PMR (one relapse), three of necrotizing myositis or acute rhabdomyolysis, three of systemic vasculitis (one EGPA, two SHP), two of ITP, and one each of relapsed rheumatoid arthritis, relapsed AOSD, and PL7-positive anti-synthetase syndrome with interstitial lung disease (ILD). Three other vaccine-induced IMDs were diagnosed within the study timeframe—two cases of GCA following seasonal influenza vaccination and a PMR following a second pneumococcal vaccination. Table 1 summarizes the demographics, diagnoses, COVID-19 vaccines, treatments, and outcomes of the patients. The patients’ mean age was 67 years (50–90 years), and 15 (56%) were women. The causative vaccines were ChAdOx1 (Vaxzevria®, AstraZeneca, Oxford, UK), BNT162b2 (Comirnaty®, Pfizer-BioNTech, New York, NY, USA), and mRNA-1273 (Spikevax®, Moderna, Cambridge, MA, USA) in 7, 18, and 2 patients, respectively. The IMD started after a first vaccine dose in 14 patients (52%), a second dose in seven patients (26%), and a third (booster) dose in six patients (22%). All three patients with acute IMNM, or rhabdomyolysis, had a negative or normal workup including serologic tests for HIV, herpes viruses, HTLV1 + 2, hepatitis A, B, and C, EBV, CMV, parvovirus, serum protein electrophoresis, antinuclear antibody test, anti-ds-DNA, ENA panel, DOT-myositis, C3, C4, rheumatoid factor, and ANCA. They all had widespread muscle inflammation with edema on MRI and a muscle biopsy demonstrating IMNM. Of the 12 GCA cases, nine were biopsy-proven. The delay between vaccination and GCA onset averaged 6 days (2–20 days). Three patients had permanent visual loss (two at diagnosis, one during an early relapse), bilaterally in one. All but three of the patients presented with an ESR > 60 mm/h (mean 92 mm/h) and a CRP level > 7 mg/dL (mean 12.3 mg/dL). The incidence of GCA in 2021 was higher than expected even after taking account of an upward trend (Figure 1).
Precipitating/etiologic factors: A potential etiologic factor or trigger, other than COVID-19 vaccination, was detected twice. A patient on statin for 3 years without muscle problems before receiving a booster dose of BNT162b2 (Case 19), tested positive for serum anti-HMG-CoA reductase antibody. One patient (Case 9) received seasonal influenza vaccination without early side effects, and 1 week later a booster dose of BNT162b2. In this patient, the systemic GCA began 6 days after COVID-19 vaccination.
HLA-DRB1/DQB1 typing: The most frequent HLA-DRB1 alleles were DRB1*04 (eight patients) and DRB1*11 (seven patients), whereas only three patients had HLA-DRB1*01. Most HLA-DQB1 alleles were DQB1*03 (14 patients, including 12 with GCA or PMR) and DQB1*02 (7 patients) (Table 2). No patients were positive for HLA-DQB1*01. Notably, 7 of 12 (58%) GCA patients, including both familial cases, had DRB1*04 alleles. There was no significant difference in the frequencies of HLA-DRB1 alleles among GCA/PMR subsets, and HLA-DRB1*04 was the most frequent allele (54%) (Table 3).
Treatments and outcomes: De-challenge (i.e., spontaneous remission or short-lived treatment without relapse) was demonstrated in three patients—two with IMNM (Cases 18 and 19) and one with ITP (Case 25). All but one of the patients (minor relapse of childhood-onset HSP) received first-line, often high-dose, glucocorticoid treatment, and 13 (50%) underwent additional treatments. All the GCA patients received high-dose glucocorticoid treatment, and most are currently undergoing tapering. One patient achieved remission after a 9-month prednisone course. Additional weekly subcutaneous tocilizumab was required for five GCA or PMR patients. One patient died from intractable rhabdomyolysis, despite intensive immunosuppressive treatment, whereas four patients (15%) had permanent damage from GCA (bilateral blindness), EGPA (bilateral median nerve palsy), or antisynthetase syndrome (restrictive lung disease). Twelve of sixteen eligible patients agreed to complete their COVID-19 vaccination during a quiescent phase of IMD, among whom 11 did so (crossover with an mRNA-based vaccine for two patients). Only two re-challenged patients experienced a disease flare—one GCA patient (Case 1) who reported a self-limited episode of polymyalgia rheumatica after the second vaccination and the patient with EGPA (Case 20), who experienced a mild flare of multiple mononeuropathy 3 days following a fourth mRNA-based (mRNA-1273, Moderna®) vaccine dose.

4. Discussion

4.1. Relationship between COVID-19 Vaccines and Subsequent IMDs

Vaccine-induced IMDs—including GCA, PMR, IMNM, AAV, HSP, AOSD, and ITP—have long been described but are rare [8,9,10,11,12,13]. We report herein a series of incident cases of IMDs following COVID-19 vaccination, recruited in the Internal Medicine Department of our University Hospital during the period of widespread vaccination. Some other trigger was present only in two patients. In these two patients (GCA, IMNM), the first symptoms of IMD occurred less than 1 week after COVID-19 vaccination. A causative relationship between vaccination and subsequent IMD is conjectural in the 27 patients, although re-challenge in two patients (Cases 1 and 20) resulted in a limited disease flare, reinforcing the hypothesis of a causal relationship between COVID-19 vaccination and GCA. The nine other re-challenged patients completed their vaccination schedule, up to two additional shots, without experiencing disease relapse. Significantly, re-vaccination was attempted during a quiescent phase of treated illness in these patients, which may have prevented them from disease flare-up. The patient with AOSD (Case 24) received her first two vaccine shots during treatment with low-dose methotrexate, without harm, and the offending booster shot while untreated for 4 months. Finally, de-challenge was rare (i.e., one in eight patients). Therefore, a causal relationship between COVID-19 vaccination and subsequent IMDs is not supported by our data. Nevertheless, the strong temporal relationship between the two events raises legitimate safety concerns about COVID-19 vaccines in these patients.

4.2. Incidence of IMDs after COVID-19 Vaccination

Although the regional IMD incidence following COVID-19 vaccination could not be calculated from our hospital-based recruitment, it might be not negligible, especially in individuals over 50 years of age. In a study of neurological IMDs occurring within 4 weeks of SARS-CoV-2 vaccination, the population-based incidence was 1/11,000 [16]. These data do not challenge the validity of vaccination programs against SARS-CoV-2 in 2021, in view of the great severity of the disease. However, the relatively frequent occurrence and potential seriousness of vaccine-induced IMDs warrant the implementation of customized vaccination policies if the disease becomes more benign.

4.3. Types of Incriminated COVID-19 Vaccines

The three types of available COVID-19 vaccines were implicated in IMDs. The higher frequency of BNT162b2-induced IMDs reflects the predominant use of this vaccine in 2021 in France. This is consistent with other case series [14,15,16,17], although other conditions, such as cerebral venous thrombosis and optic neuropathy reported to occur following COVID-19 vaccination have been markedly associated with the use of a specific vaccine [24,25]. Conversely, mRNA vaccines have inherent adjuvant properties that might have induced more adverse immune effects by generating Th17 inflammatory responses [26,27,28]. Finally, this and other studies indicate that IMDs can emerge at a variety of time points during vaccination schedules, typically after the first dose.

4.4. Patient’s Age of Onset and Gender

We found a slight female predominance (56%), and patients were mostly middle-aged or older. In the study by Watad et al., 15 of 27 (56%) patients were female and the mean age was 53 years (20–83 years) [14]. In the study by Kaulen et al., patients were mostly females (ratio 3.2:1) and had a median age of 50 years [16]. In a report on 19 immune-mediated events temporally associated with COVID-9 vaccination, only four patients (21%) were <50 years of age [15]. Regarding medical history, most (89%) patients in this study had new-onset IMDs, in agreement with other investigators [15,16,17], but not with the report by Watad et al., in which most COVID-19 vaccine-induced IMDs were flares of an underlying autoimmune or rheumatic disease [14]. Different settings, types of recruitment, and study designs may best explain the age-and-sex disparities among case series.

4.5. COVID-19 Vaccine-Induced Giant Cell Arteritis or Polymyalgia Rheumatica

GCA/PMR was the main vaccine-related subset of IMDs, accounting for 59% of the cases. Notably, GCA represented 44% of the cases and 23% (11 of 47) of all new GCA cases in the Internal Medicine Department over the 17-month study. Including a patient with GCA following influenza vaccination, the proportion of post-vaccine GCA was 21% (e.g., 7 of 34 patients) in 2021, contrasting sharply with a mean of 3% annually for the previous decade. There are two explanations for this unexpectedly high proportion of post-vaccine GCA cases. First, awareness of the condition is increased [9], prompting inquiries during history taking. Second, mass COVID-19 vaccination of the regional older adult population not only increased the likelihood of a chance temporal association but also exposed a large number of at-risk subjects to the trigger. Other cases of GCA [16,25,29,30,31,32,33,34] or PMR [17,35,36] temporally associated with COVID-19 vaccination have been published, suggesting the association to be not casual and that post-vaccine onset of GCA/PMR is not an exceptional occurrence [9].

4.6. Other Types of COVID-19 Vaccine-Induced Vasculitis

In contrast to GCA/PMR, other vasculitides represented only 11% of COVID-19 vaccine-induced IMDs. Although vaccination is a known trigger of vasculitis [11], the most recent literature implicates COVID-19 vaccination, mostly in the form of case reports covering the whole spectrum of vasculitides, with heterogeneous clinical presentations and variable severities [37,38,39,40,41,42,43]. New-onset or relapsing ANCA-associated necrotizing vasculitides [37,38,39,40,41] or HSP [42,43] have been described. Significantly, a recent study using the WHO global safety database (Vigibase) found increased reporting of Behçet’s syndrome, microscopic polyangiitis, livedoid vasculopathy, and urticarial vasculitis following COVID-19 mRNA vaccination [44]. Whether this finding also applies to viral vector-based COVID-19 vaccines warrants further investigation.

4.7. COVID-19 Vaccine-Induced Immune-Mediated Necrotizing Myopathy or Acute Rhabdomyolysis

Immune-mediated necrotizing myopathy/rhabdomyolysis comprised 11% of the cases. A booster effect of COVID-19 vaccination on an underlying, silent, statin-induced IMNM in the patient positive for anti-HMG-CoA reductase antibody cannot be excluded. Other cases of inflammatory myositis or acute rhabdomyolysis of variable severity following SARS-CoV-2 vaccination have been reported [16,45,46,47,48,49,50,51]. Disease severity in the patients with acute muscle disorders ranged from a self-limited illness to a rapidly fatal rhabdomyolysis, despite intensive immunosuppressive therapy [46,50,51]. The relative paucity of reports of inflammatory myositis or acute rhabdomyolysis during the worldwide COVID-19 vaccination campaign is in line with the claim of no significant increase in the incidence of dermatomyositis or polymyositis following vaccinations of any type [52].

4.8. COVID-19 Vaccine-Induced Miscellaneous IMDs

Other IMDs in this study were miscellaneous, pointing to a ubiquitous mechanism of immune-response enhancement. Cases of ILD [53,54], RA [55,56], AOSD [57,58], and ITP [59,60] following COVID-19 vaccination have been reported, supporting the hypothesis of a causative link rather than a casual association. Interrogation of the French Pharmacovigilance Network yielded 123 ITP cases, the corresponding rate of de novo or relapsed reports per million COVID-19 vaccine doses being 1.69 (95% CI 1.42-201). In this study, the rate was highest with ChAdOx1-S, particularly after the first dose (60), whereas a previous study using the Vaccine Adverse Event Reporting System (VAERS) described 77 de novo ITPs, all after mRNA-based vaccines [59]. Our finding of two de novo ITPs but no severe relapse of a preexisting ITP is in agreement with previous reports that the latter is infrequent [59,60].

4.9. HLA-DR/DQ and COVID-19 Vaccine-Induced IMDs

The results of HLA-DRB1 typing in post-COVID vaccine IMDs did not yield a noticeable pattern, except for a high rate of DRB1*04 (54%) in GCA patients. We also observed a strong predominance, of unknown significance, of DQB1*03. Furthermore, the distribution of HLA-DRB1 alleles did not differ significantly among GCA/PMR subsets (e.g., post-COVID vaccine cases; post-influenza, or pneumococcal, vaccine cases; familial cases; typical cases). The origin of GCA is unknown but genetic and environmental factors are implicated [61]. Interestingly, in our inception GCA cohort, familial aggregation of GCA was detected in 2 of 12 (17%) patients with post-COVID-19 GCA and 4 of 13 (31%) patients with post-influenza or pneumococcal vaccine, but only 15 of 388 (4%) patients without a vaccine trigger. HLA-DRB1*04 is the main genetic determinant of GCA [62] and a risk factor for ASIA [8,63]. From our observations, unadjuvanted vaccines such as the currently marketed SARS-CoV-2 vaccines can induce GCA/PMR by acting as non-specific triggers in genetically predisposed subjects (notably those with HLA-DRB1*04) possibly by strongly activating Toll-like receptor signaling [64]. Nevertheless, a global pharmacovigilance study showed a lower relative risk of GCA or PMR following COVID-19 compared to influenza vaccination [65], consistent with the hypothesis that classical adjuvant-containing vaccines have a greater risk. Indeed, HLA-DRB1*01 was found only once, and no patient carried HLA-DQB1*01; both alleles are associated with ASIA [9,63]. The mixed HLA results highlight, therefore, the complex mechanisms underlying post-COVID vaccine IMDs.

4.10. Disease Severity in COVID-19 Vaccine-Induced IMDs

The severity of vaccine-induced IMDs is a concern. Contrasting with the favorable prognosis of patients in prior case series [14,15,16,17] and a recent review of post-COVID vaccination syndromes [66], in this study, few IMDs were self-limited and benign. On the contrary, 24% of the IMDs were complicated and most patients required prolonged glucocorticoid treatment, in combination with additional immunosuppressive or immunomodulatory agents in 40% of the cases. Post-COVID-19 vaccine IMDs can, therefore, be serious. Moreover, occurrence, or flare-up, of an IMD during the course of vaccination against COVID-19 can be diagnostically challenging, especially when the disease manifests as systemic symptoms such as fatigue, headache, and musculoskeletal pain soon after vaccination. Such a pattern of IMD onset can easily be mistaken for typical systemic adverse effects of vaccination, potentially delaying diagnosis.

4.11. Revaccination against COVID-19 after COVID-19 Vaccine-Induced IMDs

Revaccination against COVID-19 was acceptable. Indeed, 11 consenting patients were re-challenged with the same, or an alternate, vaccine, up to three additional shots, without significant harm in nine patients. However, the safety of re-challenging patients who experienced a COVID-19-induced IMD, and the optimal timing of re-challenge, warrants further research.

4.12. Limitations of the Study

This study has limitations that should be noted. The study design (hospital-based) precluded any calculation of the incidence of IMDs following COVID-19 vaccine. The association of COVID-19 vaccination with IMDs included may have been a result of chance, based on the small sample size and lack of evidence of a causal association [67]. In particular, de-challenge (i.e., evidence that the adverse event diminished, as would be expected if caused by the vaccine) was seen in only three cases, and re-challenge seldom resulted in disease relapse. Conversely, we performed the first teaching hospital, department-based study including all IMDs encountered during the period of mass vaccination, with exclusion of other causes, and extended follow-up. Moreover, this study is the first to address the relationship between COVID-19 vaccine-induced IMDs, especially GCA/PMR, and HLA-DR/DQ.

5. Conclusions

Our findings indicate that adults over 50 years of age may develop an IMD following COVID-19 vaccination. However, confirmation by other large-scale studies, especially focusing on the mass COVID-19 vaccination period, is warranted. We emphasize that such IMDs are rare and do not call into question the benefit of COVID-19 vaccination, which is overall safe and effective. By contrast, early revaccination after post-vaccine IMDs should be considered on an individual basis, according to disease severity, disease control, and patient acceptance. Finally, early re-challenge with a COVID-19 vaccine in patients with controlled IMDs is feasible.

Author Contributions

Methodology, E.L., S.P. and A.-L.F.; validation, M.F.; formal analysis, E.L.; investigation, E.L., S.P., G.G., H.B. and K.-H.L.; data curation, E.L.; writing—original draft, E.L.; writing—review and editing, M.F., S.P., G.G., H.B., K.-H.L. and A.-L.F. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was conducted in compliance with good clinical practices and the principles of the Declaration of Helsinki. In accordance with French law, formal approval from an ethics committee was not required for this type of retrospective study. The research has the approval of the local ethics committee (EUDRACT: 2010-A00091-38).

Informed Consent Statement

All data concerning patients were retrospectively collected. The patients followed at the University Hospital of Limoges are informed of the use of the data in the medical file as soon as they are admitted, and the patients included are not declared opposed to the research to the Data Protection Officer (DPO). Written consent for HLA-DRB1/DQB1 genotyping was obtained from all assessed patients.

Data Availability Statement

Data is contained within the article.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Moreira, E.D.; Zerbini, C.; et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [Google Scholar] [CrossRef] [PubMed]
  2. Baden, L.R.; El Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B.; et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2021, 384, 403–416. [Google Scholar] [CrossRef] [PubMed]
  3. Falsey, A.R.; Sobieszczyk, M.E.; Hirsch, I.; Sproule, S.; Robb, M.L.; Corey, L.; Neuzil, K.M.; Hahn, W.; Hunt, J.; Mulligan, M.J.; et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine. N. Engl. J. Med. 2021, 385, 2348–2360. [Google Scholar] [CrossRef] [PubMed]
  4. Connolly, C.M.; Ruddy, J.A.; Boyarsky, B.J.; Avery, R.K.; Werbel, W.A.; Segev, D.L.; Garonzik-Wang, J.; Paik, J.J. Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases. Ann. Rheum. Dis. 2021, 80, 1100–1101. [Google Scholar] [CrossRef] [PubMed]
  5. Furer, V.; Eviatar, T.; Zisman, D.; Peleg, H.; Paran, D.; Levartovsky, D.; Zisapel, M.; Elalouf, O.; Kaufman, I.; Meidan, R.; et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: A multicentre study. Ann. Rheum. Dis. 2021, 80, 1330–1338. [Google Scholar] [CrossRef]
  6. Pavord, S.; Scully, M.; Hunt, B.J.; Lester, W.; Bagot, C.; Craven, B.; Rampotas, A.; Ambler, G.; Makris, M. Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. N. Engl. J. Med. 2021, 385, 1680–1689. [Google Scholar] [CrossRef]
  7. Guimarães, L.E.; Baker, B.; Perricone, C.; Shoenfeld, Y. Vaccines, adjuvants and autoimmunity. Pharmacol. Res. 2015, 100, 190–209. [Google Scholar] [CrossRef]
  8. Perricone, C.; Colafrancesco, S.; Mazor, R.D.; Soriano, A.; Agmon-Levin, N.; Shoenfeld, Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects. J. Autoimmun. 2013, 47, 1–16. [Google Scholar] [CrossRef]
  9. Liozon, E.; Parreau, S.; Filloux, M.; Dumonteil, S.; Gondran, G.; Bezanahary, H.; Ly, K.; Fauchais, A.L. Giant cell arteritis or polymyalgia rheumatica after influenza vaccination: A study of 12 patients and a literature review. Autoimmun. Rev. 2020, 20, 102732. [Google Scholar] [CrossRef]
  10. Iyngkaran, P.; Limaye, V.; Hill, C.; Henderson, D.; Pile, K.D.; Rischmueller, M. Rheumatoid vasculitis following influenza vaccination. Rheumatology 2003, 42, 907–909. [Google Scholar] [CrossRef]
  11. Bonetto, C.; Trotta, F.; Felicetti, P.; Alarcón, G.S.; Santuccio, C.; Bachtiar, N.S.; Pernus, Y.B.; Chandler, R.; Girolomoni, G.; Hadden, R.D.; et al. Vasculitis as an adverse event following immunization–Systematic literature review. Vaccine 2016, 34, 6641–6651. [Google Scholar] [CrossRef] [PubMed]
  12. Stübgen, J.-P. A review on the association between inflammatory myopathies and vaccination. Autoimmun. Rev. 2014, 13, 31–39. [Google Scholar] [CrossRef] [PubMed]
  13. Perricone, C.; Ceccarelli, F.; Nesher, G.; Borella, E.; Odeh, Q.; Conti, F.; Shoenfeld, Y.; Valesini, G. Immune thrombocytopenic purpura (ITP) associated with vaccinations: A review of reported cases. Immunol. Res. 2014, 60, 226–235. [Google Scholar] [CrossRef] [PubMed]
  14. Watad, A.; De Marco, G.; Mahajna, H.; Druyan, A.; Eltity, M.; Hijazi, N.; Haddad, A.; Elias, M.; Zisman, D.; Naffaa, M.; et al. Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination. Vaccines 2021, 9, 435. [Google Scholar] [CrossRef]
  15. Hočevar, A.; Tomšič, M. Immune mediated events timely associated with COVID-19 vaccine. A comment on article by Badier; et al.: “IgA vasculitis in adult patients following vaccination by ChadOx1 nCoV-19”. Autoimmun. Rev. 2021, 21, 102989. [Google Scholar] [CrossRef]
  16. Kaulen, L.D.; Doubrovinskaia, S.; Mooshage, C.; Jordan, B.; Purrucker, J.; Haubner, C.; Seliger, C.; Lorenz, H.; Nagel, S.; Wildemann, B.; et al. Neurological autoimmune diseases following vaccinations against SARS-CoV-2: A case series. Eur. J. Neurol. 2021, 29, 555–563. [Google Scholar] [CrossRef]
  17. Ottaviani, S.; Juge, P.-A.; Forien, M.; Ebstein, E.; Palazzo, E.; Dieudé, P. Polymyalgia rheumatica following COVID-19 vaccination: A case-series of ten patients. Jt. Bone Spine 2021, 89, 105334. [Google Scholar] [CrossRef]
  18. Hunder, G.G.; Bloch, D.A.; Michel, B.A.; Stevens, M.B.; Arend, W.P.; Calabrese, L.H.; Edworthy, S.M.; Fauci, A.S.; Leavitt, R.Y.; Lie, J.T.; et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990, 33, 1122–1128. [Google Scholar] [CrossRef]
  19. Dasgupta, B.; Cimmino, M.A.; Maradit-Kremers, H.; Schmidt, W.A.; Schirmer, M.; Salvarani, C.; Bachta, A.; Dejaco, C.; Duftner, C.; Jensen, H.S.; et al. 2012 provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann. Rheum. Dis. 2012, 71, 484–492. [Google Scholar] [CrossRef] [Green Version]
  20. Aletaha, D.; Neogi, T.; Silman, A.J.; Funovits, J.; Felson, D.T.; Bingham, C.O., III; Birnbaum, N.S.; Burmester, G.R.; Bykerk, V.P.; Cohen, M.D.; et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62, 2569–2581. [Google Scholar] [CrossRef]
  21. Lundberg, I.E.; Tjarnlund, A.; Bottai, M.; Werth, V.P.; Pilkington, C.; de Visser, M.; Alfredsson, L.; Amato, A.A.; Barohn, R.J.; Liang, M.H.; et al. EULAR/ACR classifica-tion criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann. Rheum. Dis. 2017, 76, 1955–1964. [Google Scholar] [CrossRef] [PubMed]
  22. Yamaguchi, M.; Ohta, A.; Tsunematsu, T.; Kasukawa, R.; Mizushima, Y.; Kashiwagi, H.; Kashiwazaki, S.; Tanimoto, K.; Matsumoto, Y.; Ota, T. Preliminary criteria for classification of adult Still’s disease. J. Rheumatol. 1992, 19, 424–430. [Google Scholar] [PubMed]
  23. Mills, J.A.; Michel, B.A.; Bloch, D.A.; Calabrese, L.H.; Hunder, G.G.; Arend, W.P.; Edworthy, S.M.; Fauci, A.S.; Leavitt, R.Y.; Lie, J.T.; et al. The American College of Rheumatology 1990 criteria for the classification of henoch-schönlein purpura. Arthritis Rheum. 1990, 33, 1114–1121. [Google Scholar] [CrossRef]
  24. Schulz, J.B.; Berlit, P.; Diener, H.-C.; Gerloff, C.; Greinacher, A.; Klein, C.; Petzold, G.C.; Piccininni, M.; Poli, S.; Röhrig, R.; et al. COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany. Ann. Neurol. 2021, 90, 627–639. [Google Scholar] [CrossRef] [PubMed]
  25. Elnahry, A.G.; Al-Nawaflh, M.Y.; Eldin, A.A.G.; Solyman, O.; Sallam, A.B.; Phillips, P.H.; Elhusseiny, A.M. COVID-19 Vaccine-Associated Optic Neuropathy: A Systematic Review of 45 Patients. Vaccines 2022, 10, 1758. [Google Scholar] [CrossRef]
  26. Echaide, M.; Labiano, I.; Delgado, M.; de Lascoiti, A.F.; Ochoa, P.; Garnica, M.; Ramos, P.; Chocarro, L.; Fernández, L.; Arasanz, H.; et al. Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination. Cancers 2022, 14, 4464. [Google Scholar] [CrossRef]
  27. Hotez, P.J.; Bottazzi, M.E.; Corry, D.B. The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement. Microbes Infect. 2020, 22, 165–167. [Google Scholar] [CrossRef]
  28. Huang, Y.-W.; Tsai, T.-F. Exacerbation of Psoriasis Following COVID-19 Vaccination: Report from a Single Center. Front. Med. 2021, 8, 812010. [Google Scholar] [CrossRef]
  29. Mejren, A.; Sørensen, C.; Gormsen, L.; Tougaard, R.; Nielsen, B. Large-vessel giant cell arteritis after COVID-19 vaccine. Scand. J. Rheumatol. 2021, 51, 154–155. [Google Scholar] [CrossRef]
  30. Cadiou, S.; Perdriger, A.; Ardois, S.; Albert, J.D.; Berthoud, O.; Lescoat, A.; Guggenbuhl, P.; Robin, F. SARS-CoV-2, polymyalgia rheumatica and giant cell arteritis: COVID19 vaccine shot as a trigger? Comments on “Can SARS-CoV-2 trigger relapse of polymyalgia rheumatica?” by Manzo et al. Joint Bone Spine 2021;88:105150. Jt. Bone Spine 2022, 89, 105282. [Google Scholar] [CrossRef]
  31. Sauret, A.; Stievenart, J.; Smets, P.; Olagne, L.; Guelon, B.; Aumaitre, O.; André, M.; Trefond, L. Case of giant cell arteritis after SARS-CoV-2 vaccination: A particular phenotype? J. Rheumatol. 2021, 49, 120. [Google Scholar] [CrossRef]
  32. Gambichler, T.; Krogias, C.; Tischoff, I.; Tannapfel, A.; Gold, R.; Susok, L. Bilateral giant cell arteritis with skin necrosis following SARS-CoV-2 vaccination. Br. J. Dermatol. 2022, 186, e83. [Google Scholar] [CrossRef] [PubMed]
  33. Anzola, A.M.; Trives, L.; Martínez-Barrio, J.; Pinilla, B.; Álvaro-Gracia, J.M.; Molina-Collada, J. New-onset giant cell arteritis following COVID-19 mRNA (BioNTech/Pfizer) vaccine: A double-edged sword? Clin. Rheumatol. 2022, 41, 1623–1625. [Google Scholar] [CrossRef] [PubMed]
  34. Ishizuka, K.; Katayama, K.; Ohira, Y. Giant cell arteritis presenting with chronic cough and headache after BNT162b2 mRNA COVID-19 vaccination. QJM Int. J. Med. 2022, 115, 621–622. [Google Scholar] [CrossRef]
  35. Vanni, E.; Ciaffi, J.; Mancarella, L.; Ursini, F. A report of conjugal polymyalgia rheumatica after SARS-CoV-2 vaccination. Rheumatology 2021, 1, 17–21. [Google Scholar]
  36. Manzo, C.; Natale, M.; Castagna, A. Polymyalgia rheumatica as uncommon adverse event following immunization with COVID-19 vaccine: A case report and review of literature. Aging Med. 2021, 4, 234–238. [Google Scholar] [CrossRef]
  37. Shakoor, M.T.; Birkenbach, M.P.; Lynch, M. ANCA-associated vasculitis following Pizer-BioNTech COVID-19 vaccine. Am. J. Kidney Dis. 2021, 78, 611–613. [Google Scholar] [CrossRef] [PubMed]
  38. Villa, M.; Diaz-Crespo, F.; Perez de Jose, A.; Verdalles, U.; Verde, E.; Ruiz, F.A.; Acosta, A.; Mijaylova, A.; Goicoechea, M. A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: Casualty or causality? Kidney Int. 2021, 100, 937. [Google Scholar] [CrossRef]
  39. Prabhahar, A.; Naidu, G.S.R.S.N.K.; Chauhan, P.; Sekar, A.; Shama, A.; Sharma, A.; Kumar, A.; Nada, R.; Rathi, M.; Kohli, H.S.; et al. ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: Case-based review. Rheumatol. Int. 2022, 42, 749–758. [Google Scholar] [CrossRef]
  40. Chan-Chung, C.; Ong, C.S.; Chan, L.L.; Tan, E.K. Eosinophilic granulomatosis with polyangiitis after COVID-19 vaccination. QJM Int. J. Med. 2022, 114, 807–809. [Google Scholar] [CrossRef]
  41. Ibrahim, H.; Alkhatib, A.; Meysami, A. Eosinophilic Granulomatosis with Polyangiitis Diagnosed in an Elderly Female After the Second Dose of mRNA Vaccine Against COVID-19. Cureus 2022, 14, e21176. [Google Scholar] [CrossRef] [PubMed]
  42. Choi, Y.; Lee, C.H.; Kim, K.M.; Yoo, W.-H. Sudden Onset of IgA Vasculitis Affecting Vital Organs in Adult Patients following SARS-CoV-2 Vaccines. Vaccines 2022, 10, 923. [Google Scholar] [CrossRef]
  43. Badier, L.; Toledano, A.; Porel, T.; Dumond, S.; Jouglen, J.; Sailler, L.; Bagheri, H.; Moulis, G.; Lafaurie, M. IgA vasculitis in adult patient following vaccination by ChadOx1 nCoV-19. Autoimmun. Rev. 2021, 20, 102951. [Google Scholar] [CrossRef] [PubMed]
  44. Mettler, C.; Terrier, B.; Treluyer, J.-M.; Chouchana, L. Risk of systemic vasculitis following mRNA COVID-19 vaccination: A pharmacovigilance study. Rheumatology 2022, 61, e363–e365. [Google Scholar] [CrossRef] [PubMed]
  45. Theodorou, D.J.; Axiotis, A.; Gianniki, M.; Tsifetaki, N. COVID-19 vaccine-related myositis. QJM Int. J. Med. 2021, 114, 424–425. [Google Scholar] [CrossRef] [PubMed]
  46. Ajmera, K.M. Fatal Case of Rhabdomyolysis Post-COVID-19 Vaccine. Infect. Drug Resist. 2021, 14, 3929–3935. [Google Scholar] [CrossRef]
  47. Maramattom, B.V.; Philips, G.; Thomas, J.; Santhamma, S.G.N. Inflammatory myositis after ChAdOx1 vaccination. Lancet Rheumatol. 2021, 3, e747–e749. [Google Scholar] [CrossRef]
  48. Tan, A.; Stepien, K.M.; Narayana, S.T.K. Carnitine palmitoyltransferase II deficiency and post-COVID vaccination rhabdomyolysis. QJM Int. J. Med. 2021, 114, 596–597. [Google Scholar] [CrossRef]
  49. Al-Rasbi, S.; Al-Maqbali, J.S.; Al-Farsi, R.; Al Shukaili, M.A.; Al-Riyami, M.H.; Al Falahi, Z.; Al Farhan, H.; Al Alawi, A.M. Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report. Am. J. Case Rep. 2022, 23, e934399. [Google Scholar] [CrossRef]
  50. Cirillo, E.; Esposito, C.; Giardino, G.; Azan, G.; Fecarotta, S.; Pittaluga, S.; Ruggiero, L.; Barretta, F.; Frisso, G.; Notarangelo, L.D.; et al. Case Report: Severe Rhabdomyolysis and Multiorgan Failure After ChAdOx1 nCoV-19 Vaccination. Front. Immunol. 2022, 13, 845496. [Google Scholar] [CrossRef]
  51. Kamura, Y.; Terao, T.; Akao, S.; Kono, Y.; Honma, K.; Matsue, K. Fatal thrombotic microangiopathy with rhabdomyolysis as an initial symptom after the first dose of mRNA–1273 vaccine: A case report. Int. J. Infect. Dis. 2022, 117, 322–325. [Google Scholar] [CrossRef] [PubMed]
  52. Orbach, H.; Tanay, A. Vaccines as a trigger for myopathies. Lupus 2009, 18, 1213–1216. [Google Scholar] [CrossRef] [PubMed]
  53. Kono, A.; Yoshioka, R.; Hawke, P.; Iwashina, K.; Inoue, D.; Suzuki, M.; Narita, C.; Haruta, K.; Miyake, A.; Yoshida, H.; et al. Correction to: A case of severe interstitial lung disease after COVID-19 vaccination. QJM Int. J. Med. 2021, 114, 805. [Google Scholar] [CrossRef] [PubMed]
  54. Park, J.Y.; Kim, J.-H.; Lee, I.J.; Kim, H.I.; Park, S.; Hwang, Y.I.; Jang, S.H.; Jung, K.-S. COVID-19 vaccine-related interstitial lung disease: A case study. Thorax 2022, 77, 102–104. [Google Scholar] [CrossRef] [PubMed]
  55. Baimukhamedov, C.; Makhmudov, S.; Botabkova, A. Seropositive rheumatoid arthritis after vaccination against SARS-CoV-2 infection. Int. J. Rheum. Dis. 2021, 24, 1440–1441. [Google Scholar] [CrossRef] [PubMed]
  56. Singh, R.; Kaur, U.; Singh, A.; Chakrabarti, S.S. Refractory hypereosinophilia associated with newly diagnosed rheumatoid arthritis following inactivated BBV152 COVID-19 vaccine. J. Med. Virol. 2022, 94, 3482–3487. [Google Scholar] [CrossRef]
  57. Magliulo, D.; Narayan, S.; Ue, F.; Boulougoura, A.; Badlissi, F. Adult-onset Still’s disease after mRNA COVID-19 vaccine. Lancet Rheumatol. 2021, 3, e680–e682. [Google Scholar] [CrossRef]
  58. Sharabi, A.; Shiber, S.; Molad, Y. Adult-onset Still’s disease following mRNA COVID-19 vaccination. Clin. Immunol. 2021, 233, 108878. [Google Scholar] [CrossRef]
  59. Lee, E.-J.; Beltrami-Moreira, M.; Al-Samkari, H.; Cuker, A.; DiRaimo, J.; Gernsheimer, T.; Kruse, A.; Kessler, C.M.; Kruse, C.; Leavitt, A.D.; et al. SARS-CoV-2 vaccination and immune thrombocytopenia in de novo and pre-existing ITP patients. Blood 2021, 139, 1564–1574. [Google Scholar] [CrossRef]
  60. Moulis, G.; Crickx, E.; Thomas, L.; Massy, N.; Mahévas, M.; Valnet-Rabier, M.-B.; Atzenhoffer, M.; Michel, M.; Godeau, B.; Bagheri, H.; et al. De novo and relapsed immune thrombocytopenia after COVID-19 vaccines: Results of French safety monitoring. Blood 2022, 139, 2561–2565. [Google Scholar] [CrossRef]
  61. Liozon, E.; Ouattara, B.; Rhaiem, K.; Ly, K.H.; Bezanahary, H.; Loustaud, V.; Letellier, P.; Drouet, M.; Vidal, E. Familial aggregation in giant cell arteritis and polymyalgia rheumatica: A comprehensive literature review including 4 new families. Clin. Exp. Rheumatol. 2009, 27 (Suppl. S52), S89–S94. [Google Scholar] [PubMed]
  62. Carmona, F.D.; Mackie, S.L.; Martín, J.-E.; Taylor, J.C.; Vaglio, A.; Eyre, S.; Bossini-Castillo, L.; Castañeda, S.; Cid, M.C.; Hernández-Rodríguez, J.; et al. A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. Am. J. Hum. Genet. 2015, 96, 565–580. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Watad, A.; Quaresma, M.; Brown, S.; Cohen Tervaert, J.M.; Rodriguez-Pint, I.; Cervera, R.; Perricone, C.; Shoenfeld, Y. Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld’s syndrome)–An update. Lupus 2017, 26, 675–681. [Google Scholar] [CrossRef] [PubMed]
  64. Ma-Krupa, W.; Kwan, M.; Goronzy, J.J.; Weyand, C.M. Toll-like receptors in giant cell arteritis. Clin. Immunol. 2005, 115, 38–46. [Google Scholar] [CrossRef]
  65. Mettler, C.; Jonville-Bera, A.-P.; Grandvuillemin, A.; Treluyer, J.-M.; Terrier, B.; Chouchana, L. Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: A global pharmacovigilance study. Rheumatology 2021, 61, 865–867. [Google Scholar] [CrossRef]
  66. Ursini, F.; Ruscitti, P.; Raimondo, V.; De Angelis, R.; Cacciapaglia, F.; Pigatto, E.; Olivo, D.; Di Cola, I.; Galluccio, F.; Francioso, F.; et al. Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: A report of 30 cases. Clin. Rheumatol. 2022, 41, 2261–2267. [Google Scholar] [CrossRef]
  67. Miller, F.; Hess, E.V.; Clauw, D.J.; Hertzman, P.A.; Pincus, T.; Silver, R.M.; Mayes, M.D.; Varga, J.; Medsger, T.A.; Love, L.A. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum. 2000, 43, 243–249. [Google Scholar] [CrossRef]
Jcm 11 07484 g001 550
Figure 1. Numbers of patients with newly diagnosed GCA, including usual GCA and post-vaccine GCA, from 1 January 2010 to 31 December 2021. Gray shading, numbers of typical (e.g., without a vaccine trigger) GCA cases; black, post-vaccine cases.
Figure 1. Numbers of patients with newly diagnosed GCA, including usual GCA and post-vaccine GCA, from 1 January 2010 to 31 December 2021. Gray shading, numbers of typical (e.g., without a vaccine trigger) GCA cases; black, post-vaccine cases.
Jcm 11 07484 g001
Table
Table 1. Data of patients with immune-mediated diseases occurring, or relapsing, following COVID-19 vaccination.
Table 1. Data of patients with immune-mediated diseases occurring, or relapsing, following COVID-19 vaccination.
PatientAge/SexConditionVaccineDoseDelay (d)Past History, Co-Morbid ConditionsTreatment for IMDsRe-ChallengeOutcome
187/FGCAm-RNA (Moderna)1st7OsteoarthritisPred 30 mg/dYes, twiceRecovered disease (13 mo, untreated for 4 mo)
282/FGCAm-RNA (Pfizer)1st10Hypertension, osteoarthritis, gastric ulcerPred 40 mg/dYes, twiceControlled disease (14 mo, Pred 3 mg/d)
370/FGCAviral vector (AstraZeneca)1st2Diabetes, hypertension, hypercholesterolemia, gouty diseasePred 40 mg/d, 2nd line TocilizumabNo (declined)Controlled disease (13 mo, Pred 7 mg/d)
490/FGCAm-RNA (Pfizer)1st3MDS (5q-), past PMR, hypertensionMP 500 mg/d × 2, Pred 50 mg/dYes, onceEarly lost to follow-up
580/MGCAm-RNA (Moderna)2nd3NoneMP 500 mg/d × 3, Pred 75 mg/d, 2nd line TocilizumabNo (declined)Relapsed disease (7 mo, Pred 15 mg/d)
665/FGCAm-RNA (Pfizer)1st3HypertensionPred 50 mg/dYes, twiceControlled disease (10 mo, Pred 6 mg/d)
759/FGCAm-RNA (Pfizer)1st4Autoimmune neutropenia, breast carcinomaPred 60 mg/d, 2nd TocilizumabNo (declined)Multiple relapses upon short tapering Pred regimen (12 mo)
868/MPMR, then GCAviral vector (AstraZeneca)2nd20Duodenal ulcerPred 50 mg/dn.a.Controlled disease (5 mo, Pred 10 mg/d)
964/MGCAm-RNA (Pfizer)3rd6Familial aggregation (GCA in sister)MP 500 mg/d × 3, Pred 80 mg/j Tocilizumabn.a.Controlled disease (3 mo, Pred 20 mg/d)
1072/MGCAm-RNA (Pfizer)3rd5Hypertension, diabetes, hypercholesterolemiaPred 60 mg/dn.a.n.a. (recently diagnosed)
1172/MGCA (aortitis)m-RNA (Pfizer)3rd1Kidney stonesPred 50 mg/dn.a.n.a. (recently diagnosed)
1269/MGCAm-RNA (Pfizer)3rd2HypercholesterolemiaPred 50 mg/dn.a.n.a. (recently diagnosed)
1362/FPMR m-RNA (Pfizer)2nd6Discogenic sciaticaPred 30 mg/d, 2nd line TocilizumabYes, once (Moderna) Relapsed disease (7 mo, Pred 9 mg/d)
1458/MPMRm-RNA (Pfizer)2nd2Hypertension, obesity, pheochromocytoma, sleep apneaPred 40 mg/dNo (declined)Controlled disease (9 mo, Pred 4 mg/d)
1569/FPMRm-RNA (Pfizer)1st14Hypertension, osteoarthritis, depressionPred 20 mg/dYes, once (3rd dose planned)Controlled disease (6 mo, Pred 5 mg/d)
1677/MPMR (late relapse)m-RNA (Pfizer)2nd10Hypertension, diabetes, prostatic carcinomaPred 20 mg/dYes (third dose)Controlled disease (8 mo, Pred stopped for 2 mo)
1764/MARviral vector (AstraZeneca)1st13Thyroid insufficiency, hypertriglyceridemiaMP 1 g/d × 3, Pred 2 mg/d, MTX, IVIG, CPMNo (prohibited)Died of uncontrolled disease (2 mo)
1859/FIMNMviral vector (AstraZeneca)1st11OsteoarthritisMP 1 g/d × 3 + IVIG, Pred 60 mg/dNo (declined)Recovered (13 mo, no treatment for 12 mo)
1962/MIMNMm-RNA (Pfizer)3rd7Hypertension, sleep apnea, nocardiosis, benign ampullomaPred 80 mg/d, IVIgGn.a.Satisfactory short-term response
2057/FAAV (EGPA)viral vector (AstraZeneca)1st14Allergic asthmaMP 1 g/d × 3, Pred 70 mg/d, RTXYes (twice, m-RNA based)Limited disease relapse (11 mo, pred 5 mg/d + RTX 500 mg every 6 mo)
2150/FSHP (late relapse)m-RNA (Pfizer)1st2Pediatric SHPColchicine, pregabalineYes, twiceRelapsed disease (10 mo, upon colchicine discontinuation)
2253/MSHP (digestive involvement)m-RNA (Pfizer)1st8NoneMP 1000 Mg/d × 4, Pred 80 mg/d, colchicineNo (declined)Controlled disease (12 mo, Pred 2.5 mg/d + colchicine)
2361/FAnti-synthetase (PL7+)m-RNA (Pfizer)2nd4HypothyroidismPred, 60 mg/d, 2nd line tacrolimusn.a.Poorly controlled disease (5 mo, Pred 15 mg/d)
2469/FAOSD relapsem-RNA (Pfizer)3rd14HypertensionPred 20 mg/d, oral methotrexaten.a.Relapsed disease (4 mo, pred 10 mg/d, methotrexate resumed)
2573/FITPviral vector (AstraZeneca)1st14Hypertension, hypercholesterolemia, COPD, atherosclerotic peripheral diseaseDex 40 mg/d × 4, Pred 60 mg/dYes, twice (m-RNA based)Recovered disease (11 mo)
2671/MITPviral vector (AstraZeneca)1st4Sleep apnea, psoriasis, benign prostate hypertrophyDex 40 mg/d × 4, Pred 70 mg/d, TRANo (declined)Failure-partial control under TRA (11 mo)
2757/FRA (late relapse)m-RNA (Pfizer) 2Sleep apneamethotrexaten.a.n.a. (recently diagnosed)
GCA, giant cell arteritis. AR, acute rhabdomyolysis. IMNM, immune-mediated necrotizing myopathy. AAV, ANCA-associated (systemic) vasculitis. EGPA, eosinophilic granulomatosis with polyangiitis. SHP, Schönlein-Henoch purpura. AOSD, adult-onset Still’s disease. RA, rheumatoid arthritis. ITP, immunologic (idiopathic) thrombocytopenic purpura. MDS, myelodysplastic syndrome. PMR, polymyalgia rheumatica. BPH, benign prostate hypertrophy. COPD, chronic obstructive pulmonary disease. Pred, prednisone. MP, methylprednisolone (pulse high dose). MTX, methotrexate. IVIG, intravenous immunoglobulins. CPM, cyclophosphamide. Dex, dexamethasone. TRA, thrombopoietin receptor agonist.
Table
Table 2. DQB1 typing of 20 patients with post-COVID-19 vaccine IMDs.
Table 2. DQB1 typing of 20 patients with post-COVID-19 vaccine IMDs.
PatientDiagnosisHLA DRB1/DQB1 Typing
Case 1GCADRB1*04:02/*08:01; DQB1*03:02/*04:02
Case 2GCADRB1*07:01/*11:04; DQB1*02:02/*03:01
Case 3GCADRB1*07:01/*07:01; DQB1*02:01/*02:02
Case 5GCADRB1*03/*04; DQB1*02/*03
Case 6GCADRB1*04:04/*11:01; DQB1*03:01/*03:02
Case 7GCADRB1*04:01/*15:01; DQB1*03:01/*06:02
Case 8GCADRB1*04:03/*15:02; DQB1*03:02/*06:01
Case 9GCADRB1*03:01/*04:01; DQB1*02:01/*03:01
Case 10GCADRB1*07:01/*13:01; DQB1*02:01/*06:03
Case 11GCADRB1*04:02/*15:01; DQB1*03:02/*06:02
Case 12GCADRB1*01:02/*11:02; DQB1*03:01/*05:01
Case 13PMRDRB1*03/*12; DQB1*02/*03
Case 14PMRDRB1*11:01/*16:01; DQB1*03:01/*05:02
Case 16PMRDRB1*13/*14; DQB1*03/*05
Case 17ARDRB1*07:01/*08:01/DQB1*02:02/*04:02
Case 18IMNMDRB1*11:04/*16:01; DQB1*03:01/*05:02
Case 19IMNMDRB1*04:01/*11:01; DQB1*--/*--
Case 23ASS (PL7+) DRB1*01:01/*17:01; DQB1*02:02/*05:01
Case 24SHPDRB1*07:01/*11:04; DQB1*03:01/*06:01
Case 27RADRB1*01:01/*13:01; DQB1*05:01/*06:01
GCA, giant cell arteritis. PMR, polymyalgia rheumatica. AR., acute rhabdomyolysis. ASS, antisynthetase syndrome. SHP, Schönlein-Henoch purpura. RA, rheumatoid arthritis.
Table
Table 3. Typing in 58 patients—50 with GCA and 8 with PMR, under various circumstances of onset.
Table 3. Typing in 58 patients—50 with GCA and 8 with PMR, under various circumstances of onset.
HLA-DRB1 AllelePost-COVID-19 Vaccine Cases
N = 14
n (%) *		Post-Other-Vaccine Cases
N = 11
n (%) †		Familial Cases
N = 17
n (%) §		Other Cases
N = 16
n (%) ¥		p-Value
DRB1*011 (7)2 (18)0 (0)2 (12.5)0.30
DRB1*033 (21)2 (18)1 (6)2 (12.5)0.63
DRB1*047 (50)4 (36)10 (59)10 (62.5)0.58
DRB1*073 (21)3 (27)7 (41)4 (25)0.68
DRB1*081 (7)1 (9)0 (0)0 (0)0.34
DRB1*090 (0)1 (9)0 (0)0 (0)0.19
DRB1*100 (0)1 (9)0 (0)0 (0)0.19
DRB1*115 (36)2 (18)5 (29)4 (25)0.83
DRB1*121 (7)0 (0)0 (0)0 (0)0.43
DRB1*132 (14)5 (45)5 (31)5 (31)0.40
DRB1*153 (21)1 (9)4 (23.5)3 (19)0.86
DRB1*161 (7)0 (0)0 (0)0 (0)0.43
* Eleven GCA and three PMR. † Seven GCA and four PMR. § Sixteen GCA and one PMR. ¥ GCA only. Post-COVID vaccine cases vs. post-other-vaccine cases vs. familial cases vs. other cases.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Liozon, E.; Filloux, M.; Parreau, S.; Gondran, G.; Bezanahary, H.; Ly, K.-H.; Fauchais, A.-L. Immune-Mediated Diseases Following COVID-19 Vaccination: Report of a Teaching Hospital-Based Case-Series. J. Clin. Med. 2022, 11, 7484. https://doi.org/10.3390/jcm11247484

AMA Style

Liozon E, Filloux M, Parreau S, Gondran G, Bezanahary H, Ly K-H, Fauchais A-L. Immune-Mediated Diseases Following COVID-19 Vaccination: Report of a Teaching Hospital-Based Case-Series. Journal of Clinical Medicine. 2022; 11(24):7484. https://doi.org/10.3390/jcm11247484

Chicago/Turabian Style

Liozon, Eric, Matthieu Filloux, Simon Parreau, Guillaume Gondran, Holy Bezanahary, Kim-Heang Ly, and Anne-Laure Fauchais. 2022. "Immune-Mediated Diseases Following COVID-19 Vaccination: Report of a Teaching Hospital-Based Case-Series" Journal of Clinical Medicine 11, no. 24: 7484. https://doi.org/10.3390/jcm11247484

APA Style

Liozon, E., Filloux, M., Parreau, S., Gondran, G., Bezanahary, H., Ly, K. -H., & Fauchais, A. -L. (2022). Immune-Mediated Diseases Following COVID-19 Vaccination: Report of a Teaching Hospital-Based Case-Series. Journal of Clinical Medicine, 11(24), 7484. https://doi.org/10.3390/jcm11247484

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop